Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 29 May 2024 Trial design discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology
- 21 Feb 2024 Status changed from not yet recruiting to recruiting.
- 13 Dec 2023 Planned initiation date changed from 30 Sep 2023 to 30 Jan 2024.